Literature DB >> 23291240

Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease.

Julius Popp1, Sabrina Meichsner, Heike Kölsch, Piotr Lewczuk, Wolfgang Maier, Johannes Kornhuber, Frank Jessen, Dieter Lütjohann.   

Abstract

The disturbances of the cholesterol synthesis and metabolism described in Alzheimer's disease (AD) may be both a consequence of the neurodegenerative process and a contributor to the pathogenesis. These putative relationships and their underlying mechanisms are not well understood. The aim of this study was to evaluate the relationship between the cerebral and extracerebral cholesterol synthesis and metabolism, and the AD pathology as reflected by CSF markers in humans. We evaluated the relationships between the plasma and the cerebrospinal fluid (CSF) concentrations of cholesterol, the cholesterol precursors lanosterol, lathosterol and desmosterol, and the cholesterol elimination products 24S-hydroxycholesterol and 27-hydroxycholesterol, and the CSF markers for AD pathology Aβ1-42 and p-tau181 in 86 subjects with normal cognition and in 107 AD patients. CSF desmosterol, cholesterol and 24S-hydroxycholesterol in the AD group, and CSF 24S-hydroxycholesterol in the control group correlated with the p-tau181 levels. Neither CSF nor plasma concentrations of the included compounds correlated with the CSF Aβ1-42 levels. In multivariate regression tests including age, gender, albumin ratio, number of the APOEε4 alleles, and diagnosis, p-tau181 levels independently predicted the CSF desmosterol, cholesterol and 24S-hydroxycholesterol concentrations. The associations remained significant for CSF cholesterol and 24S-hydroxycholesterol when analyses were separately performed in the AD group. The results suggest that alterations of CNS cholesterol de novo genesis and metabolism are related to neurodegeneration and in particular to the cerebral accumulation of phosphorylated tau.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23291240     DOI: 10.1016/j.bcp.2012.12.007

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  26 in total

Review 1.  Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis.

Authors:  Hua-Long Wang; Yan-Yong Wang; Xin-Gang Liu; Sheng-Han Kuo; Na Liu; Qiao-Yun Song; Ming-Wei Wang
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 2.  Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets.

Authors:  Lijun Dai; Li Zou; Lanxia Meng; Guifen Qiang; Mingmin Yan; Zhentao Zhang
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

Review 3.  Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine.

Authors:  Aseel Eid; Isha Mhatre; Jason R Richardson
Journal:  Pharmacol Ther       Date:  2019-03-12       Impact factor: 12.310

Review 4.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

5.  Donepezil effects on cholesterol and oxysterol plasma levels of Alzheimer's disease patients.

Authors:  Alana C Costa; Helena P G Joaquim; Valéria S Nunes; Daniel S Kerr; Guilherme S Ferreira; Orestes V Forlenza; Wagner F Gattaz; Leda Leme Talib
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-08-31       Impact factor: 5.270

Review 6.  The relationship between iron dyshomeostasis and amyloidogenesis in Alzheimer's disease: Two sides of the same coin.

Authors:  Douglas G Peters; James R Connor; Mark D Meadowcroft
Journal:  Neurobiol Dis       Date:  2015-08-22       Impact factor: 5.996

7.  Identification and characterization of prescription drugs that change levels of 7-dehydrocholesterol and desmosterol.

Authors:  Phillip A Wages; Hye-Young H Kim; Zeljka Korade; Ned A Porter
Journal:  J Lipid Res       Date:  2018-08-07       Impact factor: 5.922

Review 8.  The role of cholesterol metabolism in Alzheimer's disease.

Authors:  Jia-Hao Sun; Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-18       Impact factor: 5.590

9.  Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults.

Authors:  Ge Li; Cynthia L Mayer; Daniel Morelli; Steven P Millard; Wendy H Raskind; Eric C Petrie; Monique Cherrier; Anne M Fagan; Murray A Raskind; Elaine R Peskind
Journal:  Neurology       Date:  2017-08-18       Impact factor: 9.910

Review 10.  The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer's Disease.

Authors:  Paola Gamba; Serena Giannelli; Erica Staurenghi; Gabriella Testa; Barbara Sottero; Fiorella Biasi; Giuseppe Poli; Gabriella Leonarduzzi
Journal:  Antioxidants (Basel)       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.